Drug firm Lupin today said it has launched its Clobetasol Propionate spray, used for treating plaque psoriasis, in the American market.
The company has launched Clobetasol Propionate spray, 0.05 per cent, after receiving an approval for it from the United States Food and Drug Administration (FDA) earlier, Lupin said in a statement.
The company's product is the generic version of Galderma Laboratories, LP's Clobex spray in the same strength, it added.
As per IQVIA MAT January 2018 data, the spray had an annual sales of around USD 30.5 million in the US.
The spray is "indicated for the treatment of moderate to severe plaque psoriasis affecting up to 20 per cent body surface area in patients 18 years of age or older," Lupin said.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app